<DOC>
	<DOC>NCT01628965</DOC>
	<brief_summary>Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.</brief_summary>
	<brief_title>A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject completed the preceding trial 24307001 (NCT00537485) Subject discontinued from the preceding trial 24307001. Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 24307001. Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 24307001. Subject had persistent hallucination or delusion during trial 24307001. Subject has psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline. Subject has orthostatic hypotension or a systolic blood pressure (SBP) &lt;= 100 mmHg and has a decrease of SBP from spine to standing position &gt;= 30 mmHg at baseline. Subject has a history of epilepsy, convulsion etc. during trial 24307001. Subject develops serious ECG abnormality at the baseline. Subject has QTcinterval &gt;= 500 msec at the baseline or subject has an increase of QTcinterval &gt;= 60 msec from the baseline in the trial 24307001 and has a QTcinterval &gt; 470 msec in female or &gt; 450 msec in male at the baseline. Subject has a serum potassium level &lt; 3.5 mEq/L at the end of the taper period in trial 24307001. Subject has a total bilirubin &gt;= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or &gt;= 100 IU/L) at the end of the period in trial 24307001. Subject has BUN &gt;= 30 mg/dL or serum creatinine &gt;= 2.0 mg/dl at the end of the taper period in trial 24307001. Subject who plans pregnancy during the trial. Subject has dementia. Subject is unable to give consent. Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Parkinson's disease</keyword>
	<keyword>monotherapy</keyword>
</DOC>